Lv1
30 积分 2024-09-07 加入
Tyrosine kinase 2 inhibitors in autoimmune diseases
11小时前
已完结
Inborn errors of immunity and somatic variant phenocopies disrupting human JAK-STAT signaling
1天前
已完结
STATs, Promising Targets for the Treatment of Autoimmune and Inflammatory Diseases
1天前
已完结
Vunakizumab: First Approval
1天前
已完结
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
7天前
已完结
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
9天前
已完结
The pathogenesis of psoriatic arthritis
9天前
已完结
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
10天前
已完结
Response to Deucravacitinib in Psoriasis Patients with Prior Biologic Therapy Failures: A Retrospective Study
10天前
已完结
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
19天前
已完结
皖公网安备34019202002308
